Aroa Biosurgery Reports Positive Cash Flow and Reaffirms Growth Guidance

The latest update is out from Aroa Biosurgery Ltd ( (AU:ARX) ).

Aroa Biosurgery Limited announced its third consecutive quarter of positive net cash flow, with operating cash flow reaching NZ$1.7 million and strong customer cash receipts of NZ$22.5 million. The company reaffirmed its FY26 revenue guidance of NZ$92-100 million and normalised EBITDA of NZ$5-8 million, indicating a growth trajectory. The company also highlighted the sustained growth of its Myriad product line and the publication of two new peer-reviewed clinical studies, reinforcing the efficacy of its ECM technology. These developments are expected to strengthen Aroa’s market position and provide significant value to stakeholders.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.93 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery is a soft-tissue regeneration company based in Auckland, New Zealand, and listed on the Australian Securities Exchange. The company develops, manufactures, and distributes medical and surgical products aimed at improving healing in complex wounds and soft tissue reconstruction. Aroa’s products are derived from a proprietary extracellular matrix biomaterial, with a significant market presence in the United States.

Average Trading Volume: 227,486

Technical Sentiment Signal: Buy

Current Market Cap: A$196.7M

For detailed information about ARX stock, go to TipRanks’ Stock Analysis page.